📊 JAZZ Key Takeaways
Is Jazz Pharmaceuticals plc (JAZZ) a Good Investment?
Jazz Pharmaceuticals exhibits strong operational profitability and cash generation, but the dramatic 163.6% YoY decline in net income despite 4.9% revenue growth signals severe underlying operational challenges or significant one-time charges that undermine confidence in earnings quality. Elevated leverage (1.18x Debt/Equity) combined with weak returns on equity (6.5%) and assets (2.5%) suggest the company is struggling with capital efficiency and may face restructuring pressures.
Jazz Pharmaceuticals shows a split fundamental profile: modest top-line growth and very strong cash generation support the business, but the sharp swing to negative operating and net income raises concerns about earnings quality and cost structure. Liquidity appears solid and free cash flow is strong enough to support operations and debt service over time, yet elevated leverage and deeply negative interest coverage make sustained profitability recovery the key issue.
Why Buy Jazz Pharmaceuticals plc Stock? JAZZ Key Strengths
- Exceptional free cash flow generation of $388.5M with 36.3% FCF margin
- Strong gross margins (57.2%) and operating margins (31.5%) indicate pricing power in core business
- Adequate liquidity position with 2.04x current ratio and $1.8B cash on hand
- Robust interest coverage of 10.3x demonstrates debt serviceability despite leverage
- Strong free cash flow generation with $1.30B of FCF and a 30.4% FCF margin
- Solid liquidity profile with a 1.86x current ratio and $1.39B in cash
- Revenue is still growing year over year, indicating underlying commercial demand remains intact
JAZZ Stock Risks: Jazz Pharmaceuticals plc Investment Risks
- Unexplained 163.6% net income decline YoY contradicts revenue growth, indicating potential major impairments or restructuring charges
- Elevated debt-to-equity ratio of 1.18x constrains financial flexibility in pharmaceutical sector
- Modest 4.9% revenue growth combined with 6.5% ROE and 2.5% ROA suggests competitive pressures and poor capital deployment
- Data quality gap with missing total liabilities figure limits balance sheet transparency
- Profitability deteriorated sharply, with negative operating margin, net margin, and EPS
- High leverage with $5.36B of long-term debt and 1.24x debt-to-equity
- Negative interest coverage suggests current earnings do not adequately support financing costs
Key Metrics to Watch
- Net income trend in subsequent quarters to determine if decline is temporary or structural
- Revenue growth acceleration targeting 8%+ to demonstrate market competitiveness
- Debt reduction pathway and timeline to bring Debt/Equity below 1.0x
- Operating margin recovery and net income normalization
- Free cash flow durability relative to debt reduction and interest burden
Jazz Pharmaceuticals plc (JAZZ) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 36.3% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.04x current ratio provides a solid financial cushion.
JAZZ Profit Margin, ROE & Profitability Analysis
JAZZ vs Healthcare Sector: How Jazz Pharmaceuticals plc Compares
How Jazz Pharmaceuticals plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Jazz Pharmaceuticals plc Stock Overvalued? JAZZ Valuation Analysis 2026
Based on fundamental analysis, Jazz Pharmaceuticals plc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Jazz Pharmaceuticals plc Balance Sheet: JAZZ Debt, Cash & Liquidity
JAZZ Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Jazz Pharmaceuticals plc's revenue has grown significantly by 38% over the 5-year period, indicating strong business expansion. The most recent EPS of $6.10 reflects profitable operations.
JAZZ Revenue Growth, EPS Growth & YoY Performance
JAZZ Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $897.8M | -$92.5M | $-1.52 |
| Q3 2025 | $1.1B | -$14.6M | $3.42 |
| Q2 2025 | $1.0B | -$14.6M | $2.35 |
| Q1 2025 | $897.8M | -$14.6M | $-0.23 |
| Q3 2024 | $972.1M | -$14.6M | $2.14 |
| Q2 2024 | $957.3M | -$14.6M | $1.52 |
| Q1 2024 | $892.8M | -$14.6M | $-0.23 |
| Q3 2023 | $940.7M | $1.6M | $0.26 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Jazz Pharmaceuticals plc Dividends, Buybacks & Capital Allocation
JAZZ SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Jazz Pharmaceuticals plc (CIK: 0001232524)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JAZZ
What is the AI rating for JAZZ?
Jazz Pharmaceuticals plc (JAZZ) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are JAZZ's key strengths?
Claude: Exceptional free cash flow generation of $388.5M with 36.3% FCF margin. Strong gross margins (57.2%) and operating margins (31.5%) indicate pricing power in core business. ChatGPT: Strong free cash flow generation with $1.30B of FCF and a 30.4% FCF margin. Solid liquidity profile with a 1.86x current ratio and $1.39B in cash.
What are the risks of investing in JAZZ?
Claude: Unexplained 163.6% net income decline YoY contradicts revenue growth, indicating potential major impairments or restructuring charges. Elevated debt-to-equity ratio of 1.18x constrains financial flexibility in pharmaceutical sector. ChatGPT: Profitability deteriorated sharply, with negative operating margin, net margin, and EPS. High leverage with $5.36B of long-term debt and 1.24x debt-to-equity.
What is JAZZ's revenue and growth?
Jazz Pharmaceuticals plc reported revenue of $1.1B.
Does JAZZ pay dividends?
Jazz Pharmaceuticals plc does not currently pay dividends.
Where can I find JAZZ SEC filings?
Official SEC filings for Jazz Pharmaceuticals plc (CIK: 0001232524) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JAZZ's EPS?
Jazz Pharmaceuticals plc has a diluted EPS of $4.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is JAZZ a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Jazz Pharmaceuticals plc has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is JAZZ stock overvalued or undervalued?
Valuation metrics for JAZZ: ROE of 6.5% (sector avg: 15%), net margin of 27.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy JAZZ stock in 2026?
Our dual AI analysis gives Jazz Pharmaceuticals plc a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is JAZZ's free cash flow?
Jazz Pharmaceuticals plc's operating cash flow is $408.2M, with capital expenditures of $19.7M. FCF margin is 36.3%.
How does JAZZ compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 27.4% (avg: 12%), ROE 6.5% (avg: 15%), current ratio 2.04 (avg: 2).